Please login to the form below

Not currently logged in
Email:
Password:

UCB files Vimpat patent claims against 15 companies

Aurobindo, Glenmark, Mylan, Ranbaxy and Sandoz all face legal challenge over generic versions of UCB's epilepsy drug

UCB sign

UCB has filed lawsuits against 15 different companies it claims have infringed the patent of its epilepsy drug Vimpat.

The Belgium-based biopharma company filed the suits in the US District Court for the district of Delaware in the US following the original submission of an Abbreviated New Drug Application (ANDA) by Aurobindo to market its own version of Vimpat (lacosamide) in the US.

UCB hit back against this with a lawsuit demanding that Aurobindo not be allowed to market generic Vimpat until March 2022, when it says the patent of the drug's patent is due to expire.

Other companies have also submitted their own ANDAs, however, encouraged by the prospect of a 180-day exclusivity period for the first generic product to successfully challenge UCB's Vimpat patent.

These other firms include major players in the generics market, such as Glenmark, Apotex, Mylan, Ranbaxy, Sandoz, Sun Pharma and Watson, who all want to market their own versions of the drug for use as an adjunctive therapy in the treatment for partial-onset seizures in adults with epilepsy.

Zydus, ScieGen, Hetero USA, Breckenridge, Amneal, Alembic and Accord make up the other companies facing a legal challenge from UCB.

Vimpat has been a strong growth driver for UCB since its approval in 2008, making $353m in the US for the 12 months ending March 31, 2013, according to IMS, and UCB will be keen to retain exclusivity.

Along with other recent launches like Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease and the Neupro (rotigotine) patch for Parkinson's disease, Vimpat has helped UCB weather the loss of patent protection for previous lead drug Keppra (levetiracetam) and continue the company's growth.

"During 2012, UCB reached the 'crossover point' where the net sales of our new core medicines Cimzia, Vimpat and Neupro [exceeded] those of Keppra, UCB's leading medicine for many years," noted UCB's CEO Roch Doliveux in the company's financial statement for 2012.

23rd July 2013

From: Sales, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...

Infographics